LFB190
Cancers with EP300 loss-of-function mutations (e.g., NSCLC, Bladder Cancer)
Pre-clinicalActive
Key Facts
Indication
Cancers with EP300 loss-of-function mutations (e.g., NSCLC, Bladder Cancer)
Phase
Pre-clinical
Status
Active
Company
About Leapfrog Bio
Leapfrog Bio is a private, pre-clinical stage biotech leveraging its novel OncoSLX platform to discover and develop precision oncology therapies. The company's approach screens clinically tested drugs against a wide array of cancer driver mutations to identify potent pharmacogenetic relationships, aiming to accelerate development and reduce translational risk. Its lead program, LFB190, is a BET inhibitor targeting EP300 loss-of-function mutant cancers, with a Phase 1b/2a trial planned for 2026. A second program, LFB083, targets PIK3CA gain-of-function mutations, representing a significant unmet need in cancers like breast cancer.
View full company profile